Alimera Sciences
Acquired
- Employees
- 51–200
- Business Model
- B2B
- Website
- alimerasciences.com
- Last Round
- Venture RoundFeb 2014
About
Alimera Sciences was a global pharmaceutical company focused on diseases affecting the retina. Its flagship product, ILUVIEN, is a sustained-release intravitreal implant approved for diabetic macular edema and non-infectious uveitis. The company served patients and physicians across the US and international markets before being acquired by ANI Pharmaceuticals in September 2024.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account